


Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	
Sheet	1	of		Filing Date	even date herewith
				First Named Inventor	ZAGURY et al.
				Group Art Unit	1648
				Examiner Name	PAKEN, S
				Attorney Docket Number	ZAGURY3A

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	AA				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Office ³	Foreign Patent Number	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	AB	EP	0 330 359	A2	BIO-RAD LABORATORIES, INC.	08-30-1989
	AC					

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				
J	AD	ZAGURY et al., "Antibodies to the HIV-1 Tat Protein Correlated With Nonprogression to AIDS: A Rationale for the Use of Tat Toxoid as an HIV-1 Vaccine," J. of Human Virology, May/June 1998., Vol. 1, No. 4, pp. 282-292.				
	AE	RODMAN et al., "Epitopes for Natural Antibodies of Human Immunodeficiency Virus (HIV)-negative(normal) and HIV-positive sera are coincident with two key functional sequences of HIV tat Protein," Proc. of Nat. Academy of Sciences, USA, August 1993, Vol. 90, pp. 7719-7723.				
	AF	RODMAN et al., "Natural Antibodies. Early host defense against HIV?," International Conf. on AIDS, 1992, Vol. 8, No. 2, page A74 (abstract No. POA 2429).				
	AG	RE et al., "Antibody Against Human Immunodeficiency Virus type 1 (HIV-1). Tat Protein may have influenced the progression of AIDS in HIV-1 infected hemophiliac patients," Clinical and Diagnostic Laboratory Immunology, March 1996, Vol. 3, No. 2, pp. 230-232.				
	AH	RE et al., "Effect of Antibody to HIV-1 Tat Protein on Viral replication in vitro and progression of HIV-1 disease in vivo," J. of Acquired Immune Deficiency Syndromes and Human Retrovirology. December 1, 1995, Vol. 10, No. 4, pp. 408-416.				
↓	AI	RODMAN et al., "Human Immunodeficiency virus (HIV) Tat reactive antibodies present in normal HIV-negative sera and depleted in HIV-positive sera. Identification of the epitope," J. of Experimental Medicine. 1 May 1992, Vol. 175, No. 5, pp. 1247-1253.				


Examiner Signature		Date Considered	06/22/03
--------------------	---	-----------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

#7

Substitute for form 1449A/PTO



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1 of 1

Complete if Known

RECEIVED

Application Number	09/763,369
Filing Date	May 22, 2001
First Named Inventor	ZAGURY et al.
Group Art Unit	1648
Examiner Name	PARKER, S
Attorney Docket Number	ZAGURY3A
	MAY 01 2003 TECH CENTER 1600 10/29/03

RECEIVED
MAY 01 2003
TECH CENTER 1600
10/29/03

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document Number	Kind Code ⁴ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
✓ AJ		5,108,891		CROXSON	04-28-1992	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Office ³	Foreign Patent Number	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
✓ AK		DE	195 14 089 A1		DEUTSCHES KREBSFORSCH	10-24-1998		Yes

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
✓ AL		GRINGERI et al., Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients, <u>Journal of Human Virology</u> , 1:293-298 (1998)	
✓ AM		REISS et al., Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals, <u>Journal of Acquired Immune Deficiency Syndromes</u> , 4:165-172 (1991)	
✓ AN		GIBELLINI et al., Antibody to HIV-1 tat protein, a key molecule in HIV-1 pathogenesis. A brief review, <u>Microbiologica</u> , 24:197-205 (20010)	

Examiner Signature

Date Considered

06/22/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NOTICE OF REFERENCES CITED

APPLICANTS : Zagury, D., and J.-F. Zagury

U.S. PATENT DOCUMENTS

*	DOCUMENT NUMBER	DATE	NAME(S)	CLASS	SUBCLASS	FILING DATE


FOREIGN PATENT DOCUMENTS

*	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS	

OTHER REFERENCES (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

*	Reiss, P., et al., 1991, "Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and ptease in predicting development of AIDS in HIV-1 infected individuals.", J. Acquir. Immune Defic. Syndr. 4:165-172.
	Franchini, G., et al., 1987, "Spectrum of natural antibodies against five HTLV-III antigens in infected individuals: correlation of antibody prevalence with clinical status.", Blood 69(2):437-441.
	Krone, W. J. A., et al., 1988, "Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo.", J. Med. Virol. 26:261-270.
	Donovan, R. M., et al., 1996, "Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons.", J. Infect. Dis. 174:401-3.
	Pedersen, C., et al., 1992, "The effect of treatment with zidovudine with or without acyclovir on HIV p24 antigenaemia in patients with AIDS or AIDS-related complex.", AIDS 6:821-825.
	Molina, J.-M., et al., 1994, "Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression.", AIDS 8:27-33.
	Lafeuillade, A., et al., 1994, "Correlation between surrogate markers, viral load, and disease progression in HIV-1 infection.", J. Acquir. Immune Defic. Syndr. 7:1028-1033.
	Letvin, N., 1998, "Progress in the development of an HIV-1 vaccine.", Science 280:1875-1880.
	Johnston, M. I., 2000, "The role of nonhuman primate models in AIDS vaccine development.", Mol. Med. Today 6:267-270.
	Burton, D. R., and J. P. Moore, 1998, "Why do we not have an HIV vaccine and how can we make one?", Nature Med. Vaccine Suppl. 4(5):495-498.

		Lee, T.-H., 1997, "Acquired immunodeficiency disease vaccines: design and development.", in <i>AIDS: Biology, Diagnosis, Treatment and Prevention, fourth edition</i> , DeVita, V. T., et al., eds., Lippincott-Raven Publishers, pp. 605-616.

 Jeffrey S. Parkin, Ph.D.	DATE	* A COPY OF THIS REFERENCE IS NOT BEING FURNISHED WITH THIS OFFICE ACTION. (SEE MPEP SECTION 707.05(a)).
	06/22/03	PAGE 2 OF 2

SERIAL NUMBER

09/763,369

Art Unit

1648

Attachment to
Paper Number

04022004

NOTICE OF REFERENCES CITED

APPLICANTS : Zagury, D., and J.-F. Zagury

U.S. PATENT DOCUMENTS


*		DOCUMENT NUMBER	DATE	NAME(S)	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS	

* OTHER REFERENCES (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

*	Rudman, T. C., et al., 1992, "Human immunodeficiency virus (HIV) Tat reactive antibodies present in normal HIV-negative sera and depleted in HIV-positive sera. Identification of the epitope", J. Exp. Med. 176:1247-1253.

EXAMINER  Jeffrey S. Parkin, Ph.D.	DATE 04/02/04	* A COPY OF THIS REFERENCE IS NOT BEING FURNISHED WITH THIS OFFICE ACTION. (SEE MPEP SECTION 707.05(a)).
		PAGE 2 OF 2